AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
Morgan Stanley lowered the firm’s price target on AbbVie (ABBV) to $224 from $231 and keeps an Overweight rating on the shares following ...
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...
Hosted on MSN14h
AbbVie’s stock plummets over 12% after schizophrenia drug flops in Phase II trialsAbbVie’s stock price fell over 12% after emraclidine, an investigational anti-psychotic being evaluated for the treatment of ...
Zacks.com on MSN13h
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY GainsAbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company ...
Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.
AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
Trump's presidency is expected to support the US oil industry, potentially increasing domestic supply and impacting global ...
2-Year U.S. Treasury Note Continuous Contract $102.652-0.016-0.02% 5-Year U.S. Treasury Note Continuous Contract $106.719-0.023-0.02% 10-Year U.S. Treasury Note Continuous Contract $109.859-0.047 ...
This is 3x the increase of the Dow Index during this period. Is the price of gold too volatile for the average investor? Gold is no more volatile than the stock market. Gold prices can have sudden ups ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback